Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2022 - 2026)

Zentalis Pharmaceuticals has reported Change in Accured Expenses over the past 5 years, most recently at -$1.5 million for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 63.93% year-over-year to -$1.5 million; the TTM value through Mar 2026 reached -$14.7 million, down 116.95%, while the annual FY2025 figure was -$17.3 million, 3.92% up from the prior year.
  • Change in Accured Expenses for Q1 2026 was -$1.5 million at Zentalis Pharmaceuticals, down from -$733000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $11.8 million in Q2 2024 and troughed at -$15.2 million in Q1 2024.
  • A 5-year average of -$608411.8 and a median of -$1.4 million in 2023 define the central range for Change in Accured Expenses.
  • On a YoY basis, Change in Accured Expenses climbed as much as 368.48% in 2024 and fell as far as 980.72% in 2024.
  • Year by year, Change in Accured Expenses stood at $5.0 million in 2022, then soared by 105.88% to $10.4 million in 2023, then crashed by 124.64% to -$2.6 million in 2024, then skyrocketed by 71.39% to -$733000.0 in 2025, then crashed by 97.95% to -$1.5 million in 2026.
  • Business Quant data shows Change in Accured Expenses for ZNTL at -$1.5 million in Q1 2026, -$733000.0 in Q4 2025, and -$2.0 million in Q3 2025.